30063PAA3
Exact Sciences Corporation
Could not find a ticker for this position, may be a filing error
A diagnostics company focused on early cancer screening, Exact Sciences makes Cologuard—a stool-based test people collect at home to spot colorectal cancer, a noninvasive alternative to a colonoscopy. Founded in 1995 in Massachusetts by Stanley Lapidus and Anthony Shuber, it built Cologuard alongside the Mayo Clinic, and the FDA cleared the test in 2014. The name blends "colo" for colon and "guard," underscoring the test's protective role.
CONVERTIBLEUnderlying: EXASCUSIP: 30063PAA3HealthcareUS1 derivative reporter
1% Convertible Senior Notes due 15-Jan-2025
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
